Ratings by Wells Fargo (Yanan Zhu)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/12/2026 | Metagenomi Inc | MGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | Engene Holdings Inc. | ENGN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/7/2026 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/14/2026 | Spyre | SYRE | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2026 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
64.59 (79.07) |
22.42% | Details | |
| 3/9/2026 | uniQure BV | QURE | Upgrade | Overweight (Equal Weight) |
14.27 (47.93) |
235.88% | Details | |
| 3/3/2026 | Intellia Therapeutics | NTLA | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 3/3/2026 | uniQure BV | QURE | Downgrade | Equal Weight (Overweight) |
15.63 (14.27) |
-8.7% | Details | |
| 2/27/2026 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/23/2026 | Arcellx Inc. | ACLX | Downgrade | Equal Weight (Overweight) |
64.11 (115.07) |
79.49% | Details | |
| 2/20/2026 | Spyre | SYRE | Maintain | Overweight (N/A) |
|
Details | ||
| 1/20/2026 | Rapt Therapeutics | RAPT | Downgrade | Equal Weight (Overweight) |
35.10 (58.02) |
65.3% | Details | |
| 1/20/2026 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/11/2025 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/7/2025 | Intellia Therapeutics | NTLA | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/5/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/31/2025 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/28/2025 | Intellia Therapeutics | NTLA | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 10/23/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/21/2025 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2025 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/3/2025 | Editas Medicine | EDIT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/25/2025 | NewAmsterdam Pharma Co NV | NAMS | New Coverage | Overweight (N/A) |
25.00 (31.16) |
24.64% | Details | |
| 8/14/2025 | Metagenomi Inc | MGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Autolus Therapeutics plc | AUTL | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/13/2025 | Fate Therapeutics | FATE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2025 | Arcturus Therapeutics | ARCT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Avidity Biosciences | RNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Intellia Therapeutics | NTLA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2025 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/24/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/17/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/17/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/14/2025 | Metagenomi Inc | MGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/13/2025 | Affimed Therapeutics | AFMD | Downgrade | Equal Weight (Overweight) |
0.69 (0.18) |
-73.91% | Details | |
| 5/8/2025 | Sarepta Therapeutics | SRPT | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/30/2025 | Regulus Therapeutics | RGLS | Downgrade | Equal Weight (Overweight) |
3.37 (8.16) |
142.14% | Details | |
| 4/11/2025 | Sarepta Therapeutics | SRPT | New Coverage | Overweight (N/A) |
50.31 (17.46) |
-65.3% | Details | |
| 3/27/2025 | Regulus Therapeutics | RGLS | Upgrade | Overweight (Equal Weight) |
1.29 (8.16) |
532.56% | Details | |
| 3/18/2025 | Metagenomi Inc | MGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2025 | Engene Holdings Inc. | ENGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/6/2025 | Fate Therapeutics | FATE | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/24/2024 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/13/2024 | Editas Medicine | EDIT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/12/2024 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/11/2024 | Editas Medicine | EDIT | Downgrade | Equal Weight (Overweight) |
2.23 (2.76) |
23.77% | Details | |
| 11/12/2024 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Editas Medicine | EDIT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2024 | Editas Medicine | EDIT | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2024 | Spyre | SYRE | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 7/26/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/24/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2024 | Avidity Biosciences | RNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Avidity Biosciences | RNA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/20/2024 | Autolus Therapeutics plc | AUTL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2024 | Spyre | SYRE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/22/2024 | Engene Holdings Inc. | ENGN | New Coverage | Overweight (N/A) |
14.85 (1.70) |
-88.55% | Details | |
| 4/1/2024 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2024 | Metagenomi Inc | MGX | New Coverage | Overweight (N/A) |
12.04 (1.25) |
-89.62% | Details | |
| 3/1/2024 | Spyre | SYRE | Upgrade | Overweight (Equal Weight) |
27.44 (97.95) |
256.96% | Details | |
| 2/21/2024 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2024 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2024 | Autolus Therapeutics plc | AUTL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/28/2023 | Gracell Biotechnologies Inc | GRCL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/27/2023 | Gracell Biotechnologies Inc | GRCL | Downgrade | Equal Weight (Overweight) |
9.92 (10.25) |
3.33% | Details | |
| 12/21/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2023 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2023 | Aeglea Biotherapeutics | AGLE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/9/2023 | Fate Therapeutics | FATE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/1/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/16/2023 | Alaunos Therapeutics Inc. | TCRT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/16/2023 | Aeglea Biotherapeutics | AGLE | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/11/2023 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2023 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/25/2023 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Autolus Therapeutics plc | AUTL | Maintain | Overweight (N/A) |
|
Details | ||
| 4/12/2023 | Aeglea Biotherapeutics | AGLE | Downgrade | Equal Weight (Overweight) |
0.26 (12.01) |
4519.23% | Details | |
| 3/27/2023 | Gracell Biotechnologies Inc | GRCL | New Coverage | Overweight (N/A) |
1.98 (10.25) |
417.68% | Details | |
| 3/27/2023 | Fate Therapeutics | FATE | New Coverage | Equal Weight (N/A) |
5.39 (2.11) |
-60.85% | Details | |
| 3/27/2023 | Autolus Therapeutics plc | AUTL | New Coverage | Overweight (N/A) |
1.82 (1.61) |
-11.54% | Details | |
| 3/27/2023 | Alaunos Therapeutics Inc. | TCRT | New Coverage | Overweight (N/A) |
0.47 (2.15) |
357.45% | Details | |
| 3/27/2023 | Affimed Therapeutics | AFMD | New Coverage | Overweight (N/A) |
0.66 (0.18) |
-72.73% | Details | |
| 1/4/2023 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2023 | Editas Medicine | EDIT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/4/2023 | Avidity Biosciences | RNA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Aeglea Biotherapeutics | AGLE | Upgrade | Overweight (Equal Weight) |
0.50 (12.01) |
2302% | Details | |
| 10/25/2022 | Applied Genetic Technologies Corp. | AGTC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/18/2022 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/4/2022 | Applied Genetic Technologies Corp. | AGTC | Downgrade | Equal Weight (Overweight) |
0.27 (0.39) |
44.44% | Details | |
| 3/11/2022 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2022 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2021 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/14/2021 | Rapt Therapeutics | RAPT | Maintain | Overweight (N/A) |
|
Details | ||
| 4/19/2021 | Avidity Biosciences | RNA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2021 | argenx SE | ARGX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/13/2021 | Editas Medicine | EDIT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/10/2020 | Editas Medicine | EDIT | Upgrade | Overweight (Equal Weight) |
43.18 (2.76) |
-93.61% | Details | |
| 10/23/2020 | argenx SE | ARGX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/19/2020 | Momenta Pharmaceuticals | MNTA | Downgrade | Equal Weight (Overweight) |
30.81 (52.48) |
70.33% | Details | |
| 11/25/2019 | Rapt Therapeutics | RAPT | New Coverage | Overweight (N/A) |
20.70 (35.10) |
69.57% | Details | |
| 9/27/2019 | argenx SE | ARGX | New Coverage | Equal Weight (N/A) |
116.16 (909.08) |
682.61% | Details |
